40 Comments
 

Damn I hate to do this, but I guess I can try my hand at a ranking. 

Tier 1) CVP HC (the rest of the list is only HC-focused boutiques, but CVP HC is so strong right now that I feel they have to be included). 

Tier 2) Leerink, MTS, Cain Brothers

Tier 3) Torreya, Edgemont, TripleTree (these guys might be T2, tbh)

Tier 4) HC Wainwright, Ziegler (pretty sure they focus on healthcare public finance), Berkery Noyes, Brentwood

I'm only a 2nd year analyst, so take it with a grain of salt. 

 

It’s Blair and TT that clean up a large majority of the activity in HCIT. Multiples being paid on some of these deals in the past couple of years are almost unbelievable.

 

Can only really speak to the Biopharma vertical but I’ll take a crack. I see it this way:

  • CVP hands down runs Biopharma sell side M&A. They are prob on like ~50% of deals in the $5-10B size range (this is a guess, it could be more tbh). All the top bulges fight over the remaining market share - leaving not much for other banks. Theres very few people who kill it in biotech m&a
  • Lazard kills it for buyside advisory and has a great deal sheet when being on that side of the table. Not sure how they keep getting deal flow considering they did the Gilead / galapagos deal but that’s another topic…
  • evercore is also solid but I’ve heard all their advisory work is out of NY. They are not as strong on the cap markets side of things
  • in terms of capital markets for bulges JPM is probably the best, Goldman does lots of deals but they kind of suck as lead bank - they don’t do thoughtful work and I get the sense they only get mandated at times strictly because companies want Goldman on their s-1… MS also kills it. CS / UBS / Citi are less strong
  • for MM banks - all mainly do equities. Jefferies is clear top dog here and is really a “mini bulge”. Lots of lead left spots. Cowen is next up followed closely by Leerink - both have excellent HC groups that do thoughtful work. Great research as well. Up next is probably Piper which is somewhat of a rising star in the space but def not on bar with either of the previously mentioned banks.
  • HCW is pretty bush league
 

I assume you mean medical devices? If so Guggenheim has the best MedTech group on the street. 

If you're talking wearable technology/diagnostics? Hard to say since it can fall under TMT umbrella (Qatalyst was on the Google/Fitbit deal and technically Fitbit does fall under HCIT). If you're talking about telemedicine/HCIT, Blair and TT dominate the middle market as mentioned above by another poster. Lazard has to be also mentioned in the conversation, they seem to have a strong relationship with Teladoc. Helped them buy two companies, inTouch Health for I believe ~$600M and helped them merge with Livongo on a $18+ billion deal (honestly surprising how little love Lazard HC gets on here vs other EBs). This market IMO is going to be huge in 5-10 years but as of now in it's infancy, hard to determine a true leader in the vertical since 95%+ of the HCIT companies out there are likely valued in the middle market range ($150-800 million range I'd say).

 

Are like SomaLogic, Invitae, PacBio and 10x genomics considered medtech? I think tools and diagnostics is like a vertical within medtech but I dont think Guggenheim is doing those but more traditional medical devices.

 

As mentioned, CVP absolutely kills it (although they are not only HC focused). The other big players are JPM, MS, GS (not purely HC focused though). Those four firms basically dominate the entire large cap healthcare space across all products. 
 

After those four, there’s a fairly sizable drop and then you have Evercore, Lazard and Jefferies. They’re occasionally on large cap stuff, but not as common as prior four. 
 

After that you have another pretty big drop and have MTS Partners, Leerink, and HC Wainwright. These are basically HC only and focused on LMM space. Leerink is pretty heavy on biotech and does surprising amount of capital markets. 
 

Most of $1Bn+ HC seems to be dominated by a few firms. CVP kills it in advisory. JPM/MS/GS are active across all products given advisory expertise and balance sheet

 

JPM/MS/GS are pretty interchangeable. Usually one of them will be top on any given year in M&A and equity. GS/MS aren’t as aggressive on debt. Don't think JPM is consistently top anymore. I want to say they lost an important banker. The team at JPM is also substantially larger than the other two. 
Only put CVP high up because they are on mega cap pharma deals consistently and punch above their weight. 

 

Dominate the middle market HC services and very well respected (I work at one of their client's and our CEO who doesn't really like bankers, trusts them). Listen to a few of the MDs interviews and they're extremely knowledgeable. A lot of university hospitals M&A go through them so it's obvious academic clients trust them (which in healthcare, I think is pretty tough to do as an outsider).

Their DCM capabilities also help them get a solid amount of deal flow when M&A is slow. HCIT business is up and coming.

I would say it's hard to compare them to the other banks discussed. It's more comparable IMO to other MM HC banks.

 

Inventore rerum eos mollitia aut eos voluptas. Cumque autem odit at minus ex. Omnis nihil eos cumque.

Occaecati velit ipsa exercitationem quia voluptatem aut vitae. Deserunt molestiae suscipit omnis sed at repellendus laboriosam. Sint expedita harum dicta qui. Sed neque ut quam. Voluptas autem aut placeat quod ducimus et.

Delectus tempora fuga porro qui. Quo cupiditate eius fugiat ut nemo quaerat. Mollitia rem beatae est dicta. Fuga modi quo et doloribus et laudantium molestiae.

A et maxime ab sed ab rerum optio. Aut sit dolorum asperiores. Quis ea porro nisi voluptas nesciunt non.

 

Quam quos qui reiciendis. Autem maiores consequatur asperiores. Dolorum voluptas suscipit saepe.

Eos possimus ullam ut nihil. Velit eos voluptas doloremque ipsum rerum architecto nihil. Eligendi explicabo exercitationem ex cum molestias. Placeat enim voluptas nihil cumque asperiores odit. Eaque et est doloribus numquam. Minima autem aut accusantium at.

Quas omnis aperiam autem et. Et magni architecto tempore quia est. Sed dolore fugit consequatur provident culpa nihil ut. Expedita qui ullam nobis odio veniam. Aut fugit eum error quae omnis excepturi enim. Vel provident voluptatem sint itaque similique quaerat.

Libero ipsum et dolores facilis. Molestiae earum molestiae a quae ut et. Quia placeat autem consequatur accusamus.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
dosk17's picture
dosk17
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”